Drug Profile
Research programme: ophthalmological and bone disorder therapies - Optigen
Latest Information Update: 26 Mar 2007
Price :
$50
*
At a glance
- Originator Optigen Technologies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteogenesis imperfecta; Retinitis pigmentosa
Most Recent Events
- 04 Sep 2003 Preclinical trials in Osteogenesis imperfecta in Ireland (unspecified route)
- 04 Sep 2003 Preclinical trials in Retinal disorders in Ireland (unspecified route)